Positron Emission Tomography-Computed Tomography in Liver Imaging

Seminars in Ultrasound, CT and MRI

Volumn 34, Issue 1, 2013, Pages 66-80

  Sharma, Bhuey ^a   Martin, Axel ^b   Zerizer, Imene ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CARBON 11; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; YTTRIUM 90;

ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOGRAPHY; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER INJURY; LIVER METASTASIS; LIVER TRANSPLANTATION; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

FLUORODEOXYGLUCOSE F18; HUMANS; LIVER; LIVER NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84873486750     PISSN: 08872171     EISSN: 15585034     Source Type: Journal    
DOI: 10.1053/j.sult.2012.11.006     Document Type: Article

References (95)

1. Townsend D.W., Beyer T.A. Combined PET/CT scanner: The path to true image fusion. Br J Radiol 2002, 75:s24-s30.
2. Drzezga A., Souvatzoglou M., Eiber M., et al. First clinical experience with integrated whole-body PET/MR: Comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 2012, 53(6):845-855.
3. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: Applications and challenges in oncology. Am J Roentgenol 2007, 188:1622-1635.
4. Phelps M.E., Hoflman E.J., Muillari N.A., et al. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975, 16(3):210-224.
5. Alavi A., Kung J.W., Zhuang H.M. Implications of PET-based molecular imaging on the current and future practice of medicine. Semin Nucl Med 2005, 34:56-69.
6. Flier J.S., Mueckler M.M., Usher P. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235:1492-1495.
7. Monakhov N.K., Neistadt E.L., Shavlovskil M.M., et al. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978, 61:27-34.
8. Knox W.E., Jamdar S.C., P.A. Davis Hexokinase, differentiation, and growth rates of transplanted tumours. Cancer Res 1970, 30:2240-2244.
9. Brown R.S., Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993, 72(10):2979-2985.
10. Di Chiro G., DeLazPaz R.L., Brooks R.A., et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982, 32:1323-1329.
11. Di Chiro G., Oldfield E., Wright D.C., et al. Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roentgenol 1998, 150:189-197.
12. Wahl R.L., Quint L.E., Greenough R.L., et al. Staging of mediastinal non- small cell lung cancer with FDG PET, CT and fusion images: Preliminary prospective evaluation. Radiology 1994, 191:371-377.
13. Vitola J.B., Delbeke D., Meranze S.G., et al. Positron emission tomography with [18F] fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996, 78:2216-2222.
14. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144(5):646-674.
15. Nguyen Q.D., Challapalli A., Smith G., et al. Imaging apoptosis with positron emission tomography: 'Bench to bedside' development of the caspase-3/7 pecific radiotracer [(18)F]ICMT-11. Eur J Cancer 2012, 48(4):432-440.
16. Belhocine T., Steinmetz N., Hustinx R., et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002, 8(9):2766-2774.
17. Nagengast W.B., Lub-de Hooge M.N., Oosting S.F., et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011, 71(1):143-153.
18. Miao Z., Ren G., Jiang L., et al. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging 2011, 38(11):1977-1984.
19. Morgan B. Opportunities and pitfalls of cancer imaging in clinical trials. Nat Rev Clin Oncol 2011, 517-527. 10.1038/nrclinonc.2011.62.
20. Lalani T., Rosen M.P., Blake M.A., et al. Expert Panel of Gastrointestinal Imaging. ACR Appropriateness Criteria liver lesion-initial characterization. Am Coll Radiol 2010, 8.
21. Delbeke D., Martin W.H., Sandler M.P. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998, 133:510-516.
22. Kubota R., Yamada S., Kubota K. Nontumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 1992, 33:1972-1980.
23. Horton K., Bluemke D., Hruban R., et al. CT and MR imaging of benign hepatic and biliary tumours. Radiographics 1999, 19:431-451.
24. Berger K.L., Nicholson S.A., Dehdashti F. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000, 174(4):1005-1008.
25. Vigrain V., Boulos L., Vullierme M.P., et al. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics 2000, 20:379-397.
26. Delbeke D., Martin W.H., Sandler M.P. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998, 133:510-516.
27. Lopez A., Reyes O., Reyes M.D. Focal nodular hyperplasia (FNH): A potential cause of false-positive positron emission tomography. Clin Nucl Med 2005, 30(9):636-637.
28. Patel P.M., Alibazoglu H., Ali A. 'False positive' uptake of FDG in a hepatic adenoma. Clin Nucl Med 1997, 22(7):490-491.
29. Sanli Y., Bakir B., Kuyumcu S., et al. Hepatic adenomatosis may mimic metastatic lesions of liver with 18F-FDG PET/CT. Clin Nucl Med 2012, 37(7):697-698.
30. Esschert J.W., Bieze M., Beuers U.H. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging 2011, 38:436-440.
31. Jinnouchi N.M., Hamada N., Sueyoshi K., et al. FDG PET/CT findings of mesenchymal hamartoma of the liver in an adult. Clin Nucl Med 2009, 34(5):327-329.
32. Nguyen B. F-18 FDG PET imaging of disseminated sarcoidosis. Clin Nucl Med 2007, 32(1):53-54.
33. Liu Y., Ghesani N.V., L.S. Zuckier Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med 2010, 40:294-315.
34. Khan M.A., Combs C.S., Brunt E.M., et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000, 32(5):792-797.
35. Trojan J., Schroeder O., Raedle J., et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999, 94(11):3314-3319.
36. Delbeke D., Martin W.H., Sandler M.P., et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998, 133(5):510-515.
37. Park J.W., Kim J.H., Kim S.K., et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008, 49(12):1912-1921.
38. Sugiyama M., Sakahara H., Torizuka T., et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004, 39(10):961-968.
39. Nagaoka S., Itano S., Ishibashi M., et al. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: Preliminary findings. Liver Int 2006, 26(7):781-788.
40. Kawaoka T., Aikata H., Takaki S., et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 2009, 39(2):134-142.
41. Wudel L.J., Delbeke D., Morris D., et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003, 69(2):117-124.
42. Hatano E., Ikai I., Higashi T., et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006, 30(9):1736-1741.
43. Seo S., Hatano E., Higashi T., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumour differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007, 13(2 Pt 1):427-433.
44. Kornberg A., Freesmeyer M., Barthel E., et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009, 9(3):592-600.
45. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
46. Torizuka T., Tamaki N., Inokuma T., et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994, 35(12):1965-1969.
47. Paudyal B., Oriuchi N., Paudyal P., et al. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 2007, 18(6):1469-1473.
48. Eckel F., Herrmann K., Schmidt S., et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med 2009, 50(9):1441-1447.
49. Ho C.L., Yu S.C., Yeung D.W. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003, 44(2):213-221.
50. Ho C.L., Chen S., Yeung D.W., et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007, 48(6):902-909.
51. Yamamoto Y., Nishiyama Y., Kameyama R., et al. Detection of hepatocellular carcinoma using 11C-choline PET: Comparison with 18F-FDG PET. J Nucl Med 2008, 49(8):1245-1248.
52. Talbot J.N., Fartoux L., Balogova S., et al. Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010, 51(11):1699-1706.
53. Morimoto Y., Tanaka Y., Ito T., et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobil Pancreat Surg 2003, 10:432-440.
54. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer 2000, Liver Cancer Study Group of Japan, Kanehara, Tokyo, Japan.
55. Neumaier C.E., Bertolotto M., Perrone R., et al. Staging of hilar cholangiocarcinoma with ultrasound. J Clin Ultrasound 1995, 23:173-178.
56. Kim T.K., Choi B.I., Han J.K., et al. Peripheral cholangiocarcinoma of the liver: Two-phase spiral CT findings. Radiology 1997, 204:539-543.
57. Persson A., Dahlstrom N., Smedby O. Volume rendering of three-dimensional drip infusion CT cholangiography in patients with suspected obstructive biliary disease: A retrospective study. Br J Radiol 2005, 78:1078-1085.
58. Zandrino F., Benzi L., Ferretti M.L., et al. Multislice CT cholangiography without biliary contrast agent: Technique and initial clinical results in the assessment of patients with biliary obstruction. Eur Radiol 2002, 12:1155-1161.
59. Elsayes K.M., Narra V.R., Yin Y., et al. Focal hepatic lesions: Diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. Radiographics 2005, 25:1299-1320.
60. Romagnuolo J., Bardou M., Rahme E. Magnetic resonance cholangiopancreatography: A meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003, 139:547-557.
61. Sodickson A., Mortele K.J., Barish M.A., et al. Three-dimensional fast-recovery fast spin-echo MRCP: Comparison with two-dimensional single-shot fast spin-echo techniques. Radiology 2006, 238:549-559.
62. Kim T., Murakami T., Takahashi S., et al. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. Am J Roentgenol 1999, 173:393-398.
63. Braga H.J., Imam K., Bluemke D.A. MR imaging of intrahepatic cholangiocarcinoma: Use of ferumoxides for lesion localization and extension. Am J Roentgenol 2001, 177:111-114.
64. Kluge R., Schmidt F., Caca K., et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001, 33:1029-1035.
65. Kim Y.J., Yun M., Lee W.J., et al. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003, 30:1467-1472.
66. Kato T., Tsukamoto E., Kuge Y., et al. Clinical role of (18)FFDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002, 29:1047-1054.
67. Petrowsky H., Wildbrett P., Husarik D.B., et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006, 45:43-50.
68. Jadvar H., Henderson R.W., Conti P.S. F-18 fluorodeoxyglucose positron emission tomography and positron emission tomography: Computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 2007, 31:223-228.
69. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006, 244(2):254-259.
70. Niekel M., Bipat S., Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: A meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010, 257(3):674-684.
71. Koh D.M., Brown G., Riddell A.M., et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion weighted imaging (DWI) alone and in combination. Eur Radiol 2008, 18(5):903-910.
72. Kong G., Jackson C., Koh D.M., et al. The use of 18F-FDG PET/CT in colorectal liver metastases-Comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008, 35(7):1323-1329.
73. De Geus-Oei L.F., van Laarhoven H.W., Visser E.P., et al. Chemotherapy response evaluation with FDG PET in patients with colorectal cancer. Ann Oncol 2007, 19:348-352.
74. Lubezky N., Metser U., Geva R., et al. The role and limitations of 18-fluoro-2- deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: Comparison with operative and pathological findings. J Gastrointest Surg 2007, 11:472-478.
75. Tan M.C., Linehan D.C., Hawkins W.G., et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007, 11:1112-1119.
76. Riegger C., Herrmann J., Nagarajah J., et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 2012, 39(5):852-863.
77. Constantinidou A., Martin A., Sharma B. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: A large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011, 22(2):307-314.
78. Eubank W.B., Mankoff D.A. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005, 35:84-99.
79. Santiago J.F., Gonen M., Yeung H., et al. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006, 50:61-67.
80. Anderson G.S., Brinkmann F., Soulen M.C. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003, 28(3):192-197.
81. Donckier V., Van Laethem J.L., Goldman S., et al. (F-18) fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumour destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003, 84(4):215-223.
82. Antoch G., Vogt F.M., Veit P., et al. Assessment of liver tissue after radiofrequency ablation: Findings with different imaging procedures. J Nucl Med 2005, 46(3):520-525.
83. Gallowitsch H.J., Kresnik E., Gasser J., et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: A comparison to conventional imaging. Invest Radiol 2003, 38(5):250-256.
84. Isasi C.R., Moadel R.M., Blaufox M.D. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005, 90(2):105-112.
85. Constantinidou A., Martin A., Sharma B., et al. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: A large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011, 22(2):307-314.
86. Taylor I., Bennett R., Sherriff S. The blood supply of colorectal liver metastases. Br J Cancer 1978, 38:749-756.
87. Deleporte A., Flamen P., Hendlisz A. State of the art: Radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother 2010, 11:579-586.
88. 90Y permits hepatic localization of microspheres using routine PET: Proof of concept. J Nucl Med 2011, 52(1):72-76.
89. 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. Eur J Nucl Med Mol Imaging 2010, 37(9):1654-1662.
90. Werner M.K., Brechtel K., Beyer T., et al. PET/CT for the assessment and quantification of (90)Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. Eur J Nucl Med Mol Imaging 2010, 37(2):407-408.
91. 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun 2012, 33(6):633-640.
92. Popperl G., Helmberger T., Munzing W., et al. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm 2005, 20:200-208.
93. Haug A.R., Tiega Donfack B.P., Trumm C., et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012, 53(3):371-377.
94. Szyszko T, Al Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomography. Nucl Med Commun 28 (1):15-20, 2007.
95. Zerizer I., Al-Nahhas A., Towey D., et al. The role of early (18)F-FDG PET/CT in prediction of progression-free survival after (90)Y radioembolization: Comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 2012, 30.